Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
600 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-12-31
Study Completion Date
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators are studying the use of Melatonin in non-ventilated patients over the age of 65. Primary endpoint will be assesments of delirium, with secondary endpoints to include length of stay, use of anti-psychotic medications, and mortality
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Delirium in Intensive Care by Melatonin
NCT03524937
Mechanically Ventilated Patients
COMPLETED
PHASE2/PHASE3
Prevention of Delirium in Inpatients Utilizing Melatonin
NCT02654314
Delirium
TERMINATED
PHASE3
Melatonin for Prevention of Delirium in Critically Ill Patients
NCT02615340
Delirium
UNKNOWN
PHASE2
Melatonin for Treatment of Delirium in Critically Ill Adult Patients
NCT05713877
Delirium
RECRUITING
PHASE2
Melatonin Supplementation for Delirium Prevention in Acutely Hospitalized Elderly
NCT00873379
Delirium
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Summary Melatonin is a naturally produced hormone involved in the synchronization of circadian rhythms and the sleep-wake cycle in humans. It is often given as a sleep aid and is generally well tolerated, with very few drug-drug interactions. Recent studies have shown marginal benefit in increasing amount of sleep, but have proven benefit in decreasing delirium in elderly patients on medical wards.
Delirium is a serious problem in hospitals and Intensive-Care Units (ICUs), contributing to longer hospital stays as well as morbidity and mortality. Studies have shown that each additional day of delirium increases mortality by 10%1. It is estimated that delirium costs the US healthcare system $38-$152 billion annually, and the cost of treating a delirious patient is 2.5 times higher than treating one without delirium. It is estimated that up to one third of cases of delirium are preventable. Additionally, many of the medications given in the ICU can worsen delirium, including narcotics, antipsychotics, and benzodiazepines.
Treatment of delirium consists mostly of prevention, by frequently re-orienting the individual, letting in as much natural light as possible, frequent touching, and providing a quiet place for rest. Pharmacological treatment consists mostly of antipsychotics, which often have adverse effects and can worsen delirium.
Incidents of delirium are much higher in elderly patients, up to 80% in some cohorts, as well as ICU patients. Multiple theories for this exist, including the lack of a true rest time at night, multiple sedatives that can affect sleep-wake cycle, and large amounts of noise. It is also known that elderly patients have less total sleep and more nighttime arousals, and that ICUs in particular are quite loud, especially at night. The increase in ambient noise paired with frequent interruptions in sleep for monitoring and blood draws exacerbates this problem and likely leads to a delirious state.
To our knowledge, no study has looked at melatonin's effect on elderly, non-ventilated patients in the ICU, which is the group most at risk for developing delirium. Recent studies have indicated that delirium is decreased with melatonin use in a simulated ICU environment.2 This randomized, controlled study would aim to confirm these results in an actual ICU environment.
Additionally, it is unknown what doses are most effective for treatment of delirium. Literature has shown improvement with both 3 mg and 5 mg, but recent meta-analysis have not shown benefit of one over the other. 3 Participants Multiple studies done on critically ill, non-ventilated patients in the ICU show an incidence of delirium of at least 60%, and in some cases up to 80%4. At Parkview, the highest incidence recorded was 55%, but this was with all patients. It is likely that this percentage is much higher in the elderly. Assuming an average incidence of 70%, and assuming the investigators would want to be able to detect a 20% decrease in this incidence with our intervention, the investigators would aim to enroll 600 patients (200 in each arm), with an interim analysis to be done at 300 patients to asses for harm or efficacy. This will be done by analyzing the primary outcome for a P-value of \<0.05.
Exclusion Criteria Patients with head trauma or Neurosurgical intervention Patients \<65 years of age Patients with an expected life expectancy \<48 hours Blind patients Patients with a seizure history Patients with uncontrolled hypertension Patients with a supratheraputic (\>3.0) INR Patients on strong CYP1A2 inhibitors: ciprofloxacin, fluvoxamine, methoxsalen, ofloxacin, primaquine Patients who do not speak English or Spanish
Design Upon admission to the ICU, all consecutive, eligible patients or their POA will be presented with an informed consent describing the trial (Appendix A). All patients over 65 will be screened. Attending physicians as well as Critical Care Fellows will be allowed to consent the patients. At the point of deciding to join the trial, an order will be put in the computer for "melatonin protocol". At this point, pharmacy will assign that patient to either the placebo, 3mg, or 5mg arm of the study in a 1:1:1 fashion. Physicians, pharmacists, and nursing staff will be blinded to the protocol. Melatonin dosages of 3 and 5mg will be used for the study, as recent work with higher doses has been shown to have a "carryover" effect into the following day. The placebo pill will be a small white tablet of similar size to the 3 and 5mg tablets of melatonin. It is sucrose and is regulated by the FDA as safe for human consumption. Either placebo or melatonin will be administered at 9pm with evening medications.
The treatment group will be given either the assigned dose or placebo nightly. Either PO or PT would be acceptable. The protocol will run until the patient is discharged from the hospital. Delirium will be assessed using the CAM-ICU evaluation tool in the ICU and bCAM on the floor according to pre-existing protocols. These will be assessed every 12 hours per a protocol already in place. These tools are the most widely used in the US, with multiple studies showing reliable detection of delirium. The CAM scale is attached for reference.
If a patient deteriorates while in the ICU and requires intubation, they will be continued on the protocol.
Melatonin is generally well-tolerated5, but the two most common side effects are headaches and confusion. We hope to mitigate the confusion by using a lower dose of melatonin. Incidence of headache will be tracked, and if deemed necessary by the attending physician, melatonin therapy can be stopped. Melatonin has minor interactions with Warfarin and dihydropyridine calcium channel blockers, but patient's INR (if they are on Warfarin) and BP will be tracked routinely. Melatonin is metabolized by the CYP1A2 system, and so patients on medications that are potent inhibitors of this enzyme will also be excluded from the study. There is an interaction between Melatonin and Olanzipine, which is sometimes used for treatment of delirium. There is the potential for increased sedation with this combination, but patients will be monitored in an ICU setting while receiving these medications.
Primary outcome will be incidence of delirium (using the CAM-ICU and bCAM scores) in the study population
Secondary outcomes will be:
ICU days Total Hospital days 30 and 90-day mortality Use of anti-psychotic medications for treatment of delirium (Haloperidol, Ziprasidone, Olanzapine, Quetiapine) Average Richmond Agitation and Sedation Scale (RASS) scores when delirium assessed
Hypothesis The investigators' hypothesis is that the use of melatonin will significantly decrease the incidence of delirium in the elderly, non-ventilated patient. The investigators will use an accepted P-value of \< 0.05 to determine significance. If the p-value doesn't meet significance, the null hypothesis that melatonin does not decrease the incidence of delirium in the elderly non-ventilated patient will be accepted.
Collection/Retention of information:
Patients' CAM-ICU scores are already documented in Meditech. Other variables (when patient moves to floor, when the patient is discharged) are already routinely documented. Following completion, these variables will be placed in a database and de-identified. The data will be kept for an additional 3 years to allow for further analysis if required.
Nursing staff as well as house staff will undergo a brief in-service on the study principles as well as a reminder of how to use the CAM-ICU scores.
Confidentiality:
Only the PI will see the patient's identified information before deidentifying it. To ensure patient privacy, the informed consent discussion will happen in the patient's private room
Risks:
Melatonin has been proven to safe in every patient population by multiple studies. A consensus statement by the World Sleep Foundation in 2000 confirms that there have been no significant side-effects in healthy adults. Specifically, the use of melatonin in seizure disorders is controversial, with some data showing detriment and some showing benefit. For this reason, patients with a seizure disorder have been excluded from the study. The investigators will be using USP (United States Pharmacopeia)- certified melatonin as well. USP is a non-profit organization that regulates over-the-counter (OTC) supplements in the US. Its seal verifies that the manufacturer adheres to good manufacturing practices.
The attending physician on the case can choose to withdraw the patient from the study at any time if they feel that participation is adversely affecting the patient.
Compensation:
There will be no compensation provided for participation in this study.
Benefits:
Considering the multiple studies that have suggested safety and efficacy, critically ill patients stand to benefit from a lack of delirium and possibly shorter hospital stays. This would benefit Parkview Medical Center as well.
Delirium is a serious problem in hospitals and Intensive-Care Units (ICUs), contributing to longer hospital stays as well as morbidity and mortality. Studies have shown that each additional day of delirium increases mortality by 10%1. It is estimated that delirium costs the US healthcare system $38-$152 billion annually, and the cost of treating a delirious patient is 2.5 times higher than treating one without delirium. It is estimated that up to one third of cases of delirium are preventable. Additionally, many of the medications given in the ICU can worsen delirium, including narcotics, antipsychotics, and benzodiazepines.
Treatment of delirium consists mostly of prevention, by frequently re-orienting the individual, letting in as much natural light as possible, frequent touching, and providing a quiet place for rest. Pharmacological treatment consists mostly of antipsychotics, which often have adverse effects and can worsen delirium.
Incidents of delirium are much higher in elderly patients, up to 80% in some cohorts, as well as ICU patients. Multiple theories for this exist, including the lack of a true rest time at night, multiple sedatives that can affect sleep-wake cycle, and large amounts of noise. It is also known that elderly patients have less total sleep and more nighttime arousals, and that ICUs in particular are quite loud, especially at night. The increase in ambient noise paired with frequent interruptions in sleep for monitoring and blood draws exacerbates this problem and likely leads to a delirious state.
To our knowledge, no study has looked at melatonin's effect on elderly, non-ventilated patients in the ICU, which is the group most at risk for developing delirium. Recent studies have indicated that delirium is decreased with melatonin use in a simulated ICU environment.2 This randomized, controlled study would aim to confirm these results in an actual ICU environment.
Additionally, it is unknown what doses are most effective for treatment of delirium. Literature has shown improvement with both 3 mg and 5 mg, but recent meta-analysis have not shown benefit of one over the other. 3 Participants Multiple studies done on critically ill, non-ventilated patients in the ICU show an incidence of delirium of at least 60%, and in some cases up to 80%4. At Parkview, the highest incidence recorded was 55%, but this was with all patients. It is likely that this percentage is much higher in the elderly. Assuming an average incidence of 70%, and assuming the investigators would want to be able to detect a 20% decrease in this incidence with our intervention, the investigators would aim to enroll 600 patients (200 in each arm), with an interim analysis to be done at 300 patients to asses for harm or efficacy. This will be done by analyzing the primary outcome for a P-value of \<0.05.
Exclusion Criteria Patients with head trauma or Neurosurgical intervention Patients \<65 years of age Patients with an expected life expectancy \<48 hours Blind patients Patients with a seizure history Patients with uncontrolled hypertension Patients with a supratheraputic (\>3.0) INR Patients on strong CYP1A2 inhibitors: ciprofloxacin, fluvoxamine, methoxsalen, ofloxacin, primaquine Patients who do not speak English or Spanish
Design Upon admission to the ICU, all consecutive, eligible patients or their POA will be presented with an informed consent describing the trial (Appendix A). All patients over 65 will be screened. Attending physicians as well as Critical Care Fellows will be allowed to consent the patients. At the point of deciding to join the trial, an order will be put in the computer for "melatonin protocol". At this point, pharmacy will assign that patient to either the placebo, 3mg, or 5mg arm of the study in a 1:1:1 fashion. Physicians, pharmacists, and nursing staff will be blinded to the protocol. Melatonin dosages of 3 and 5mg will be used for the study, as recent work with higher doses has been shown to have a "carryover" effect into the following day. The placebo pill will be a small white tablet of similar size to the 3 and 5mg tablets of melatonin. It is sucrose and is regulated by the FDA as safe for human consumption. Either placebo or melatonin will be administered at 9pm with evening medications.
The treatment group will be given either the assigned dose or placebo nightly. Either PO or PT would be acceptable. The protocol will run until the patient is discharged from the hospital. Delirium will be assessed using the CAM-ICU evaluation tool in the ICU and bCAM on the floor according to pre-existing protocols. These will be assessed every 12 hours per a protocol already in place. These tools are the most widely used in the US, with multiple studies showing reliable detection of delirium. The CAM scale is attached for reference.
If a patient deteriorates while in the ICU and requires intubation, they will be continued on the protocol.
Melatonin is generally well-tolerated5, but the two most common side effects are headaches and confusion. We hope to mitigate the confusion by using a lower dose of melatonin. Incidence of headache will be tracked, and if deemed necessary by the attending physician, melatonin therapy can be stopped. Melatonin has minor interactions with Warfarin and dihydropyridine calcium channel blockers, but patient's INR (if they are on Warfarin) and BP will be tracked routinely. Melatonin is metabolized by the CYP1A2 system, and so patients on medications that are potent inhibitors of this enzyme will also be excluded from the study. There is an interaction between Melatonin and Olanzipine, which is sometimes used for treatment of delirium. There is the potential for increased sedation with this combination, but patients will be monitored in an ICU setting while receiving these medications.
Primary outcome will be incidence of delirium (using the CAM-ICU and bCAM scores) in the study population
Secondary outcomes will be:
ICU days Total Hospital days 30 and 90-day mortality Use of anti-psychotic medications for treatment of delirium (Haloperidol, Ziprasidone, Olanzapine, Quetiapine) Average Richmond Agitation and Sedation Scale (RASS) scores when delirium assessed
Hypothesis The investigators' hypothesis is that the use of melatonin will significantly decrease the incidence of delirium in the elderly, non-ventilated patient. The investigators will use an accepted P-value of \< 0.05 to determine significance. If the p-value doesn't meet significance, the null hypothesis that melatonin does not decrease the incidence of delirium in the elderly non-ventilated patient will be accepted.
Collection/Retention of information:
Patients' CAM-ICU scores are already documented in Meditech. Other variables (when patient moves to floor, when the patient is discharged) are already routinely documented. Following completion, these variables will be placed in a database and de-identified. The data will be kept for an additional 3 years to allow for further analysis if required.
Nursing staff as well as house staff will undergo a brief in-service on the study principles as well as a reminder of how to use the CAM-ICU scores.
Confidentiality:
Only the PI will see the patient's identified information before deidentifying it. To ensure patient privacy, the informed consent discussion will happen in the patient's private room
Risks:
Melatonin has been proven to safe in every patient population by multiple studies. A consensus statement by the World Sleep Foundation in 2000 confirms that there have been no significant side-effects in healthy adults. Specifically, the use of melatonin in seizure disorders is controversial, with some data showing detriment and some showing benefit. For this reason, patients with a seizure disorder have been excluded from the study. The investigators will be using USP (United States Pharmacopeia)- certified melatonin as well. USP is a non-profit organization that regulates over-the-counter (OTC) supplements in the US. Its seal verifies that the manufacturer adheres to good manufacturing practices.
The attending physician on the case can choose to withdraw the patient from the study at any time if they feel that participation is adversely affecting the patient.
Compensation:
There will be no compensation provided for participation in this study.
Benefits:
Considering the multiple studies that have suggested safety and efficacy, critically ill patients stand to benefit from a lack of delirium and possibly shorter hospital stays. This would benefit Parkview Medical Center as well.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Delirium
Melatonin
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
DOUBLE
Participants
Caregivers
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Melatonin 5mg
This arm will be given 5mg tablets of Melatonin nightly for the duration of their hospital stay
Group Type
ACTIVE_COMPARATOR
Melatonin
Intervention Type
DRUG
Patients will receive Melatonin at 2 different doses or a placebo
Melatonin 3mg
This arm will be given 3mg tablets of Melatonin nightly for the duration of their hospital stay
Group Type
ACTIVE_COMPARATOR
Melatonin
Intervention Type
DRUG
Patients will receive Melatonin at 2 different doses or a placebo
Placebo
This arm will be given a Sucrose tablet nightly for the duration of their hospital stay
Group Type
PLACEBO_COMPARATOR
Melatonin
Intervention Type
DRUG
Patients will receive Melatonin at 2 different doses or a placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Melatonin
Patients will receive Melatonin at 2 different doses or a placebo
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-ventilated Patients over the age of 65
Exclusion Criteria
* Patients with head trauma or Neurosurgical intervention
* Patients \<65 years of age
* Patients with an expected life expectancy \<48 hours
* Blind patients
* Patients with a seizure history
* Patients with uncontrolled hypertension
* Patients with a supratheraputic (\>3.0) INR
* Patients on strong CYP1A2 inhibitors: ciprofloxacin, fluvoxamine, methoxsalen, ofloxacin, primaquine
* Patients who do not speak English or Spanish
* Patients \<65 years of age
* Patients with an expected life expectancy \<48 hours
* Blind patients
* Patients with a seizure history
* Patients with uncontrolled hypertension
* Patients with a supratheraputic (\>3.0) INR
* Patients on strong CYP1A2 inhibitors: ciprofloxacin, fluvoxamine, methoxsalen, ofloxacin, primaquine
* Patients who do not speak English or Spanish
Minimum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MICE Trial Group
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parkview Medical Center
Pueblo, Colorado, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1092-7. doi: 10.1164/rccm.200904-0537OC. Epub 2009 Sep 10.
Reference Type
BACKGROUND
Huang HW, Zheng BL, Jiang L, Lin ZT, Zhang GB, Shen L, Xi XM. Effect of oral melatonin and wearing earplugs and eye masks on nocturnal sleep in healthy subjects in a simulated intensive care unit environment: which might be a more promising strategy for ICU sleep deprivation? Crit Care. 2015 Mar 19;19(1):124. doi: 10.1186/s13054-015-0842-8.
Reference Type
BACKGROUND
Chen S, Shi L, Liang F, Xu L, Desislava D, Wu Q, Zhang J. Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials. Mol Neurobiol. 2016 Aug;53(6):4046-4053. doi: 10.1007/s12035-015-9350-8. Epub 2015 Jul 21.
Reference Type
BACKGROUND
Bourne RS, Mills GH. Melatonin: possible implications for the postoperative and critically ill patient. Intensive Care Med. 2006 Mar;32(3):371-9. doi: 10.1007/s00134-005-0061-x. Epub 2006 Feb 14.
Reference Type
BACKGROUND
Arendt J. In what circumstances is melatonin a useful sleep therapy? Consensus statement, WFSRS focus group, Dresden, November 1999. J Sleep Res. 2000 Dec;9(4):397-8. doi: 10.1111/j.1365-2869.2000.00229.x. No abstract available.
Reference Type
BACKGROUND
Artemiou P, Bily B, Bilecova-Rabajdova M, Sabol F, Torok P, Kolarcik P, Kolesar A. Melatonin treatment in the prevention of postoperative delirium in cardiac surgery patients. Kardiochir Torakochirurgia Pol. 2015 Jun;12(2):126-33. doi: 10.5114/kitp.2015.52853. Epub 2015 Jun 30.
Reference Type
BACKGROUND
Bellapart J, Boots R. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth. 2012 Apr;108(4):572-80. doi: 10.1093/bja/aes035.
Reference Type
BACKGROUND
Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit Care. 2008;12(2):R52. doi: 10.1186/cc6871. Epub 2008 Apr 18.
Reference Type
BACKGROUND
Chakraborti D, Tampi DJ, Tampi RR. Melatonin and melatonin agonist for delirium in the elderly patients. Am J Alzheimers Dis Other Demen. 2015 Mar;30(2):119-29. doi: 10.1177/1533317514539379. Epub 2014 Jun 18.
Reference Type
BACKGROUND
Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, Nakamura H; DELIRIA-J Group. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014 Apr;71(4):397-403. doi: 10.1001/jamapsychiatry.2013.3320.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MICE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Use of Melatonin for Delirium Prevention in Medically Hospitalized Patients
NCT06509191
RECRUITING
PHASE2/PHASE3
Melatonin and Sleep in Preventing Delirium in the Hospital
NCT02597231
COMPLETED
PHASE1/PHASE2
Efficacy of the Administration of Melatonin 5mg in the Prevention of Delirium in Older Adults Hospitalized in the Emergency Department
NCT04187807
UNKNOWN
NA
Effects of Melatonin on Insomnia Symptoms in Older Adults
NCT00230737
COMPLETED
PHASE2
Melatonin for Delirium Prophylaxis
NCT02282241
WITHDRAWN
PHASE4
Effect of Melatonin on Sleep Quality in Patients Dementia
NCT03066518
COMPLETED
PHASE4
Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients
NCT02536417
COMPLETED
PHASE3
Oral Melatonin in Critically Ill High-risk Patients
NCT00470821
COMPLETED
PHASE4
Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults
NCT03165695
WITHDRAWN
PHASE4
Exogenous Melatonin in Intensive Care Unit Chronodisruption
NCT03708341
RECRUITING
PHASE3
The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU
NCT03931070
COMPLETED
PHASE4
The Basel BOMP-AID Randomized Trial
NCT03438526
RECRUITING
PHASE4
Oral Bedtime Melatonin in Critically Ill Patients
NCT06156059
NOT_YET_RECRUITING
PHASE4
Melatonin 3mg and 5mg Compared to Cognitive Behavioral Therapy for Insomnia (CBT-I) in the Treatment of Insomnia
NCT02798367
UNKNOWN
PHASE2/PHASE3
A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Pharmacokinetic Study
NCT06801379
RECRUITING
EARLY_PHASE1
Delirium Reduction With Ramelteon
NCT05069428
RECRUITING
PHASE4
Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms
NCT03826563
COMPLETED
NA
The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery
NCT02691013
UNKNOWN
NA
Use of Endogenous Melatonin and 6-hydroxymelatonin as Biomarkers for CYP1A2
NCT04420611
COMPLETED
Melatonin Treatment for Induced Transient Insomnia
NCT00950885
COMPLETED
NA
MIND After Surgery
NCT03785158
COMPLETED
NA
Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort
NCT01700959
COMPLETED
PHASE3
The Relative Bio-availability of Oral and Oromucosal Melatonin in Different Formulations in Healthy Human Volunteers.
NCT02107079
COMPLETED
NA
Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness
NCT00401284
COMPLETED
PHASE2
A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia
NCT00386334
COMPLETED
PHASE4